View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 24, 2021

Breathonix’s Covid-19 breath test gets provisional approval in Singapore

The Health Sciences Authority of Singapore has provisionally authorised Breathonix’s breath test for Covid-19 detection.

The Health Sciences Authority (HSA) of Singapore has provisionally authorised Breathonix’s BreFence Go COVID-19 Breath Test System for accurate disease identification in a minute.

The test is said to be the first-of-its-kind to obtain provisional authorisation in the country.

A spin-off firm from the National University of Singapore (NUS), Breathonix developed the breath test system to identify volatile organic compounds (VOCs) in an individual’s exhaled breath.

VOCs are generated by several biochemical reactions in human cells. As the VOCs signature of a healthy individual’s breath differs from an ill person, the VOCs changes are considered markers for diseases such as Covid-19.

To conduct the BreFence test, the user must blow into a disposable one-way valve mouthpiece attached to a breath sampler.

For VOCs measurement, the exhaled breath is fed into a mass spectrometer. Subsequently, a software algorithm assesses the VOCs biomarkers and delivers results within one minute.

The simple test can be performed by a trained person but does not need medically trained personnel or processing in the laboratory.

A positive result with the breath test will require a polymerase chain reaction (PCR) Covid-19 swab test for confirmation.

Breathonix CEO Dr Jia said: “Our breath test is non-invasive. Users only need to breathe out normally into the disposable mouthpiece provided, so there will not be any discomfort.

“Cross-contamination is unlikely as the disposable mouthpiece has a one-way valve and a saliva trap to prevent inhalation or saliva from entering the machine.”

Clinical trials of the breath test were carried out at three locations from June last year to April this year.

Trials in Singapore were conducted at the National Centre for Infectious Diseases and Changi Airport.

A third trial was conducted in Dubai, in partnership with the Dubai Health Authority (DHA) and the Mohammed Bin Rashid University of Medicine and Health Sciences.

The Dubai trial enrolled 2,500 subjects at DHA’s Nadd Al Hamar primary health care centre.

According to data from a pilot study carried out in Singapore on 180 subjects, the BreFence Go COVID-19 Breath Test System was found to have 93% sensitivity and 95% specificity with a machine learning algorithm.

Currently, Breathonix, along with the Singapore Ministry of Health (MOH), plans to conduct a deployment trial at Tuas Checkpoint where travellers entering the country will be screened with the breath test system.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Medical Device Network